| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/10/2003 | US20030069238 Anticancer agents; immunology diseases; antiallergens; antiinflammatory agents |
| 04/10/2003 | US20030069235 Therapy for eye infections |
| 04/10/2003 | US20030069233 Central nervous system disorders; psychological disorders; Alzheimer's disease |
| 04/10/2003 | US20030069232 Topical treatment of ocular hypertension, glaucoma, ischemic retinopathy and age-related macular degeneration with ophthalmic formulation of dopamine antagonists |
| 04/10/2003 | US20030069231 Purification of antibodies; Elisa analyzing; antidiabetic agents; skin disorders; cardiovascular agents |
| 04/10/2003 | US20030069230 Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists |
| 04/10/2003 | US20030069229 Methods of inhibiting metastases |
| 04/10/2003 | US20030069227 Vasopressin antagonist and diuretic combination |
| 04/10/2003 | US20030069226 Benzothiazole or benzothiazine derivatives of dipyrido(3,2b:2',3'-e)(1,4-diazepin-6-one |
| 04/10/2003 | US20030069224 Non-nucleoside reverse transcriptase inhibitors |
| 04/10/2003 | US20030069223 Peptidyl deformylase inhibitors used for inhibiting bacteria or preventing bacterial contamination of a cell culture medium |
| 04/10/2003 | US20030069222 Used as anti-viral agents against the HIV-1 and HIV-2 viruses. |
| 04/10/2003 | US20030069221 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 04/10/2003 | US20030069220 Method for mass medication in biological attacks |
| 04/10/2003 | US20030069218 Iron compounds, compositions , methods of making the same and uses thereof |
| 04/10/2003 | US20030069217 Methods of prevention and treatment of ischemic damage |
| 04/10/2003 | US20030069216 Interconversion of inactive 11- keto steroids with their active 11B-hydroxy equivalents, especially between cortisone and cortisol; administering a 11-beta-reductase inhibitor such as carbenoxolone |
| 04/10/2003 | US20030069215 Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate |
| 04/10/2003 | US20030069213 Oral preparation |
| 04/10/2003 | US20030069211 Injectable pamidronate disodium |
| 04/10/2003 | US20030069210 Especially imidazolyl- or 1,2,4-triazolyl- pyrimidine derivatives |
| 04/10/2003 | US20030069208 Lipophilic cation, preferably triphenylphosphonium, covalently coupled to an antioxidant moiety that is capable of being transported through the mitochondrial membrane and accumulated within the mitochondria of intact cells |
| 04/10/2003 | US20030069205 Anionic polymers including dermatan sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, heparin, dextran sulfate, pentosan polysulfate, hyaluronic acid and alginate. |
| 04/10/2003 | US20030069204 Strain of streptomyces |
| 04/10/2003 | US20030069203 Method for increasing human performance by reducing muscle fatigue and recovery time through oral administration of adenosine triphosphate |
| 04/10/2003 | US20030069202 Compositions, kits, and methods for promoting defined health benefits |
| 04/10/2003 | US20030069200 Use of glucosylceramide synthesis inhibitors in brain cancertherapy |
| 04/10/2003 | US20030069197 Probes and primers can be employed in diagnostic kits, in identifying or isolating mammalian PTTG nucleic acid, and in detecting a pathological mass associated with PTTG expression. |
| 04/10/2003 | US20030069193 Has an activity against MRSA (methicillin-resistant Staphylococcus aureus). |
| 04/10/2003 | US20030069192 May be administered along with Rutin, a Rutin congener and/or a Rutin derivative. |
| 04/10/2003 | US20030069191 Pantethinesulphonic acid and/or a salt thereof as a free-radical scavenger |
| 04/10/2003 | US20030069190 Alkali and alkaline earth metal salts of topiramate |
| 04/10/2003 | US20030069189 Administering an NF-kappa B activation inhibitor that is a proteasome inhibitor, ubiquitin pathway inhibitor, agent that interferes with activation of NF-kappa B via the ubiquitin proteasome pathway |
| 04/10/2003 | US20030069175 A cyclic peptide, e.g., cyclic (Tyr-Gly-Phe-Gly-Gly) useful for stimulating the formation of osteoblastic or fibroblastic cells, enhancing bone formation, repairing fractures, healing wounds, grafting intraosseous implants, etc. |
| 04/10/2003 | US20030069171 Mixture of glucosamine salt, chondroitin sulfate, collagen and sodium hyaluronate for treating bone disorders |
| 04/10/2003 | US20030069169 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders |
| 04/10/2003 | US20030069168 Especially flavanoids or chromones containing a rhamnose group that have selective inhibitory activity against the activated T cells |
| 04/10/2003 | US20030068821 Method for expression of small RNA molecules within a cell |
| 04/10/2003 | US20030068648 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/10/2003 | US20030068640 Diagnosing vision defects in mammals; obtain tissue sample, extract nucleotide sequences, detect mutaion in tigr allele, presence of mutation indicates vision defects |
| 04/10/2003 | US20030068634 Measurement of cell prolferation or cell destruction; obtain cells, incubate with labeled nucleotides sequences, detect labeled nucleotides in cells |
| 04/10/2003 | US20030068429 Inulin products with improved nutritional properties |
| 04/10/2003 | US20030068407 A particulate formulation containing an oil of a vitamin, an oil containing one or more vitamin or a derivative, a gelling agent of vegetable origin having a glass transition point greater than 20 degree C. and a protein except gelatin |
| 04/10/2003 | US20030068391 Combination of an antioxidant, an antiinflammatory agent, circulatory enhancement agent, vasodilator, nerve growth regeneration agent, gycemic conrol agent, sorbitol inhibitor, lipid reduction agent, pancreatic stem cell support agent |
| 04/10/2003 | US20030068389 Antibacterial agent |
| 04/10/2003 | US20030068388 N-benzyl-16(R,S)-hydroxy-9-oxo-10E,12E,14E-octadecatrieneamide isolated from Lepidium plant material, useful for treating and preventing cancer and sexual disorder |
| 04/10/2003 | US20030068387 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |
| 04/10/2003 | US20030068386 Method of treating cancerous disease |
| 04/10/2003 | US20030068385 Fatty acids derived from concentrated fish oil and being comprised of omega fatty acids of at least 50% of the total volume, with eicosapentaenoic acid) and dehydroacetic acid at minimum limits of 30% and 10% |
| 04/10/2003 | US20030068381 Induced phase transition method for the production of microparticles containing hydrophilic active agents |
| 04/10/2003 | US20030068378 Mucosal surface-coat-forming film dosage units containing a water-soluble hydrocolloid, an effective dose of a sexual dysfunction active agent and a mucosal adhesion enhancer, wherein mucosal adhesion enhancer is a starch graft copolymer |
| 04/10/2003 | US20030068376 Mucoadhesive film made up of non-microbial hydrocolloids and an effective dose of nicotine dissolves when applied intraorally to release nicotine which is absorbed through the oramucosae and directly reaches systemic circulation |
| 04/10/2003 | US20030068374 Containing physiologically active compound slightly soluble in water, a component obtained by treating with water a polyvalent metal compound slightly soluble in water, and a biodegradable polymer; improved release-control, stability |
| 04/10/2003 | US20030068368 Solid dosage form; superior disintegration, dissolution and compression characteristics |
| 04/10/2003 | US20030068367 Systems, methods and apparatuses for manufacturing dosage forms |
| 04/10/2003 | US20030068366 Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| 04/10/2003 | US20030068364 Pro-liposomal encapsulated preparations (iv) |
| 04/10/2003 | US20030068362 Methods and formulations for the delivery of pharmacologically active agents |
| 04/10/2003 | US20030068357 Food product for lowering cholesterol levels |
| 04/10/2003 | US20030068356 Sequential drug delivery systems |
| 04/10/2003 | US20030068351 >/= 1% zinc oxide, a fungicide, a batericide, >/= 5% water-absorbing macromolecular material dispersed in a water immiscible vehicle; treating skin that is exposed to excessive amounts of moisture |
| 04/10/2003 | US20030068343 Phytosphingosine, an antioxidant, an antibacterial of at least hinokitiol and a salicylate, a polysaccharide and gorgornian extract for an anti-irittating effect on skin treated with a retinoid |
| 04/10/2003 | US20030068339 Veterinary florfenicol formulation that is syringeable under cold weather conditions |
| 04/10/2003 | US20030068338 Pharmaceutical emulsions for retroviral protease inhibitors |
| 04/10/2003 | US20030068337 Composition comprising tumor cells and extracts and method using thereof |
| 04/10/2003 | US20030068333 Cocktail of >/= 4 different plasmid DNAs encoding corresponding respiratory syncytial virus antigens, coacervated with chitosan to formulate nanospheres |
| 04/10/2003 | US20030068331 Dressing for treatment of a dermatological disease comprised of a gum resin, a topically acceptable volatile solvent, and a pharmacologically active agent |
| 04/10/2003 | US20030068330 Nerve growth factor activity potentiating agents |
| 04/10/2003 | US20030068329 Aglycone of isoflavone and a cultivation product of basidiomycetes, obtained by cultivating basidiomycetes having a beta-glucosidase activity in the presence of isoflavones-containing materials; antitumor agents |
| 04/10/2003 | US20030068309 Antioxidant combination composition and use thereof |
| 04/10/2003 | US20030068307 Administering a target cell-specific adenovirus vector, comprising an adenoviral gene essential for replication under transcriptional control of a target cell-specific transcriptional regulatory element and an anticancer agent |
| 04/10/2003 | US20030068302 Optimal compositions and methods thereof for treating HCV infections |
| 04/10/2003 | US20030068297 Contains cell growth enhancers to increase growth rate of skin cells, nutrients to support log phase growth of skin cells, extracellular matrix proteins, stimulators of extracellular matrix proteins, penetration enhancers; wound healing |
| 04/10/2003 | US20030068294 Includes at least one keratolytic and cerumenilytic cleaning agent, one bactericide agent, one yeast control agent and one anti-irritant and anti-pruriginous agent; for ear hygiene and for the prevention of otitis in dogs and cats |
| 04/10/2003 | US20030068280 Treatment of respiratory diseases |
| 04/10/2003 | US20030068279 Dispersible pharmaceutical-based dry powder composition comprising a therapeutically effective amount of pharmaceutical in combination with a pharmaceutically acceptable carrier |
| 04/10/2003 | US20030068278 Administering fine powder of active material; measured aerosol |
| 04/10/2003 | US20030068277 Particles for inhalation having sustained release properties |
| 04/10/2003 | US20030068276 Dosage forms |
| 04/10/2003 | US20030066800 Enteric coatings for drugs; sustained rlease |
| 04/10/2003 | US20030066753 Stable taurolidine electrolyte solutions |
| 04/10/2003 | US20030066525 Pressurised metered dose inhalers (MDI) |
| 04/10/2003 | US20030066524 Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage |
| 04/10/2003 | CA2722319A1 Water-in-oil emulsions with ethylene oxide groups, compostions, and methods |
| 04/10/2003 | CA2466020A1 Rsv gene expression vaccine |
| 04/10/2003 | CA2463404A1 Fragements of heat shock proteins and their use |
| 04/10/2003 | CA2462802A1 Nutrient medium for maintaining neural cells in injured nervous system |
| 04/10/2003 | CA2462675A1 Novel urea oligomers, the preparation method thereof and pharmaceutical compositions containing same |
| 04/10/2003 | CA2462647A1 6-membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | CA2462643A1 Triazepine derivatives as neurotrophic agents |
| 04/10/2003 | CA2462638A1 Methods and compositions for modulating apoptosis |
| 04/10/2003 | CA2462602A1 Double stranded rna as an adjuvant in vaccine compositions |
| 04/10/2003 | CA2462601A1 Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | CA2462594A1 Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis |
| 04/10/2003 | CA2462443A1 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease |
| 04/10/2003 | CA2462427A1 Treatment of hepatitis b virus infection with human monoclonal antibodies |
| 04/10/2003 | CA2462424A1 A novel g protein-coupled receptor, gave 10 |
| 04/10/2003 | CA2462419A1 N-heterocyclyl hydrazides as neurotrophic agents |
| 04/10/2003 | CA2462305A1 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | CA2462275A1 Novel composition of carvedilol |